Novavax (NVAX) Cash & Current Investments (2010 - 2026)

Novavax's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $562.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 23.17% year-over-year to $562.0 million; the TTM figure through Mar 2026 stood at $562.0 million (down 23.17% YoY), while the FY2025 annual figure was $505.3 million, up 25.23% from the prior year.
• Cash & Current Investments was $562.0 million for Q1 2026 at Novavax, up from $505.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $909.5 million in Q3 2024 to a low of $10.3 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $372.1 million across 5 years, with a median of $403.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Current Investments plunged 99.44% in 2022, then soared 5937.13% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $10.3 million in 2022, then gained by 1.17% to $10.4 million in 2023, then soared by 3771.01% to $403.5 million in 2024, then climbed by 25.23% to $505.3 million in 2025, then grew by 11.22% to $562.0 million in 2026.
• The last three Cash & Current Investments figures came in at $562.0 million (Q1 2026), $505.3 million (Q4 2025), and $762.9 million (Q3 2025), per Business Quant data.